Pharmaceuticals

A key trend influencing the Next Generation Tissue Biomarkers Market is advancements in genomic technologies improving precision in cancer diagnostics

March 23, 2026March 24, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Is The Market Size Of The Next Generation Tissue Biomarkers Market Expected To Change Between 2026 And 2030?

The next generation tissue biomarkers market has experienced substantial growth in its size over recent years. This market is projected to expand from $3.03 billion in 2025 to $3.42 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 12.9%. The expansion observed historically can be linked to factors such as reliance on traditional histopathology techniques, limited biomarker identification methods, a surge in oncology research, the increasing adoption of companion diagnostics, and early-stage investment in genomic and proteomic studies.

The next generation tissue biomarkers market is projected to experience substantial expansion in the coming years. This market is forecast to reach $5.51 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 12.6%. Key drivers for this growth during the forecast period include advances in next-generation sequencing technologies, the incorporation of AI-based tissue analysis, the development of spatial biology platforms, increased funding in multi-omics research, and more partnerships between pharmaceutical companies and academic institutions. Noteworthy trends anticipated for this period encompass the broader application of spatial biology and multi-omics approaches, greater uptake of digital pathology and AI analysis in diagnostics, a growing need for biomarkers in oncology and companion diagnostics, enhanced utilization of tissue biomarkers in drug discovery and development, and the integration of transcriptomic and metabolomic biomarkers for tailored precision medicine.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27363&type=smp

Which Major Factors Are Driving The Expansion Of The Next Generation Tissue Biomarkers Market?

The increasing need for personalized medicine is anticipated to drive the expansion of the next generation tissue biomarkers market in the future. This medical strategy involves customizing treatments according to a person’s genetic profile, lifestyle choices, and environmental influences. Its uptake is growing, spurred by ongoing progress in genomic technologies that enable very precise and tailored therapeutic approaches. This demand for personalized medicine is accelerating the creation of next-generation tissue biomarkers, which offer the exact, individualized data necessary to adapt treatments to each patient’s distinct tissue characteristics. For example, the Personalized Medicine Coalition, a US-based non-profit organization, reported in February 2024 that the FDA cleared 16 new personalized therapies for rare disease patients in 2023, an increase from 6 in 2022. Among the personalized treatments approved in 2023 were seven cancer drugs and three for other diseases and conditions. Consequently, the expanding demand for personalized medicine is fueling the growth of the next generation tissue biomarkers market.

How Is The Next Generation Tissue Biomarkers Market Structured Across Different Segments?

The next generation tissue biomarkers market covered in this report is segmented –

1) By Type: Genomic Biomarkers, Proteomic Biomarkers, Epigenetic Biomarkers, Transcriptomic Biomarkers, Metabolomic Biomarkers

2) By Technology: Immunohistochemistry, Next-Generation Sequencing, Mass Spectrometry (Ms)-Based Proteomics, Spatial Biology Platforms, Digital Pathology And Artificial Intelligence Analysis, Other Technologies

3) By Application: Oncology, Companion Diagnostics, Drug Discovery And Development, Neurology, Other Applications

4) By End Use: Hospitals And Reference Labs, Pharma And Biotech Companies, Academic And Research Institutes, Contract Research Organizations

Subsegments:

1) By Genomic Biomarkers: Single Nucleotide Polymorphisms, Copy Number Variations, Gene Fusions

2) By Proteomic Biomarkers: Protein Expression Levels, Post-Translational Modifications, Protein-Protein Interactions

3) By Epigenetic Biomarkers: Histone Modification Patterns, Chromatin Remodeling Biomarkers, Non-Coding Ribonucleic Acid Regulation

4) By Transcriptomic Biomarkers: Long Non-Coding Ribonucleic Acids, Circular Ribonucleic Acids, Alternative Splicing Variants

5) By Metabolomic Biomarkers: Lipid Profiles, Amino Acid Signatures, Organic Acids

Which Trends Are Shaping The Future Of The Next Generation Tissue Biomarkers Market?

Leading companies operating in the next generation tissue biomarkers market are concentrating on developing advanced solutions, such as genomic diagnostic assays and sequencing technologies, to improve the accuracy, speed, and personalization of cancer diagnosis and treatment. These genomic-based diagnostic assays and sequencing solutions involve tools and techniques that examine genetic information to identify disease-related biomarkers, enabling more precise and individualized approaches to diagnosis and therapy. For instance, in August 2024, Illumina Inc., a US-based biotechnology company, obtained FDA approval for its TruSight Oncology Comprehensive test, along with two companion diagnostics, to quickly match cancer patients to targeted therapies. The test analyzes over 500 genes from a single tissue sample, facilitating precise treatment selection for various solid tumors. It automates biomarker detection and supports 24/7 deployment, significantly reducing turnaround times and enhancing clinical efficiency, representing a modern strategy for streamlining cancer diagnostics within a regulated framework.

Which Major Players Dominate The Next Generation Tissue Biomarkers Market?

Major companies operating in the next generation tissue biomarkers market are Roche Diagnostics, Thermo Fisher Scientific Inc., LabCorp., Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Bio-Techne Corporation, Myriad Genetics Inc., NeoGenomics Laboratories Inc., Foundation Medicine Inc., NanoString Technologies Inc., PathAI Inc., Biocartis Group NV, Personalis Inc., Ultivue Inc., Indica Labs Inc., Strata Oncology Inc., Genialis Inc., Alida Biosciences Inc., Biofidelity Ltd.

Read the full next generation tissue biomarkers market report here:

https://www.thebusinessresearchcompany.com/report/next-generation-tissue-biomarkers-global-market-report

Which Region Currently Holds The Largest Share Of The Next Generation Tissue Biomarkers Market?

North America was the largest region in the next generation tissue biomarkers market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next generation tissue biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Next Generation Tissue Biomarkers Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=27363&type=smp

Browse Through More Reports Similar to the Global Next Generation Tissue Biomarkers Market 2026, By The Business Research Company

Nail Care Products Market Report 2026

https://www.thebusinessresearchcompany.com/report/nail-care-products-global-market-report

Nail Salon Market Report 2026

https://www.thebusinessresearchcompany.com/report/nail-salon-global-market-report

Nail Polish Market Report 2026

https://www.thebusinessresearchcompany.com/report/nail-polish-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795